Time from study entry to virologic failure at Weeks 24, 48 and 96 [clinicaltrials_resource:e56065ccdaeae06dee22cf2a9b3904fa]
Click here for more information about lopinavir/ritonavir
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Time from study entry to virologic failure at Weeks 24, 48 and 96 [clinicaltrials_resource:e56065ccdaeae06dee22cf2a9b3904fa]
Click here for more information about lopinavir/ritonavir
Bio2RDF identifier
e56065ccdaeae06dee22cf2a9b3904fa
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:e56065ccdaeae06dee22cf2a9b3904fa
measure [clinicaltrials_vocabulary:measure]
Time from study entry to virologic failure
time frame [clinicaltrials_vocabulary:time-frame]
at Weeks 24, 48 and 96
description
Click here for more information about lopinavir/ritonavir
identifier
clinicaltrials_resource:e56065ccdaeae06dee22cf2a9b3904fa
title
Time from study entry to virologic failure at Weeks 24, 48 and 96
@en
type
label
Time from study entry to virol ...... 065ccdaeae06dee22cf2a9b3904fa]
@en